R&D

Possible coronavirus drug identified by Australian scientists

A collaborative study led by Monash University's Biomedicine Discovery Institute (BDI) in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.

New guidelines on caring for ICU patients with COVID-19

An international team including McMaster University researchers has come together to issue guidelines for health-care workers treating intensive care unit (ICU) patients with COVID-19. The Surviving Sepsis Campaign COVID-19 panel has released 54 recommendations on such topics as infection control, laboratory diagnosis and specimens, the dynamics of blood flow support, ventilation support, and COVID-19 therapy.

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.

Favipiravir flu drug 'clearly effective' in treating COVID-19

According to the multiple news articles the drug favipiravir (sold under the brand name Avigan), developed by Fujifilm Toyama Chemical, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

Understanding how COVID-19 affects children vital to slowing pandemic

Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandemic accurately, limit the disease's spread and ensure the youngest patients get the care they need.

COVID-19: The immune system can fight back

Melbourne researchers have mapped immune responses from one of Australia's first novel coronavirus (COVID-19) patients, showing the body's ability to fight the virus and recover from the infection.

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) - a joint venture between the University of Melbourne and the Royal Melbourne hospital

New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus

CRISPR-based genetic screens have helped scientists identify genes that are key players in sickle-cell anemia, cancer immunotherapy, lung cancer metastasis, and many other diseases. However, these genetic screens are limited in scope: They can only edit or target DNA. For many regions of the human genome, targeting DNA may not be effective, and other organisms, such as RNA viruses like coronavirus or flu, cannot be targeted at all with existing DNA-targeting CRISPR screens.

Research & Development

Possible coronavirus drug identified by Australian scientists

New guidelines on caring for ICU patients with COVID-19

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

Favipiravir flu drug 'clearly effective' in treating COVID-19

Understanding how COVID-19 affects children vital to slowing pandemic

COVID-19: The immune system can fight back

New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus

More Pharma News ...